Post-earnings recap
Reported
Wed, Apr 22, 2026
EPS actual
$0.27
EPS est.
$0.25
EPS surprise
+8.00%
1-day move
-1.54%
Amneal Pharmaceuticals reported better-than-expected earnings per share, which indicates stronger profitability than analysts anticipated. However, the stock fell by 1.5% following the report, likely due to the lack of revenue information and absence of guidance, leaving investors uncertain about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.27 | $0.17 | +8.00% |
| Revenue | — | $717M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals. With a market cap of $4 billion, it plays a significant role in the pharmaceutical sector, focusing on providing affordable medications to patients and healthcare providers.
Last quarter
In Q4 2025, Amneal reported an EPS of $0.21, surpassing expectations by 27.27%. However, the stock fell 4.69% the following day, indicating mixed market reactions despite the positive earnings surprise.
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+32.05%
Avg 1-day reaction
-0.44%
Analysts expect Amneal to report solid earnings this quarter, with a consensus EPS of $0.17 and revenue of $717 million. The market is closely watching for any surprises that could impact stock performance.
Bull case
If Amneal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.
Bear case
Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its market position and lead to a significant decline in stock price.
Key metrics to watch
EPS
$0.17Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$717MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Amneal's EPS exceed the consensus estimate of $0.17?
A beat on EPS could reinforce confidence in the company's profitability and growth trajectory.
Q2
What guidance will management provide regarding future revenue growth?
Future revenue guidance will be crucial for assessing the company's market outlook and potential for continued success.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The consensus may underestimate Amneal's ability to capitalize on recent market trends, particularly in generic drug demand.
Supporting evidence
Amneal has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Recent industry trends show increasing demand for generics, which could benefit Amneal significantly.
Key risk
If Amneal's revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Amneal can maintain its growth momentum in a competitive pharmaceutical landscape.
Bull confirmed if
An EPS of $0.19 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.15 would support the bear case, raising concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±25.1%
Historical Avg
±2.9%
The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±25.1% while AMRX has averaged ±2.9% over the last 8 prints — setup is pricing rich.
30d HV
36.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
48.71%
of float
Insider
52.10%
of float
Holders
425
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
26,562,093 sh · $521.9M
8.67%
8.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Amneal beats expectations, history suggests the stock could rise by around 0.71%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.
Miss
Should the company miss estimates, the stock could decline by approximately 3.46%, indicating a strong negative reaction from the market.
The lines on the call that would change the story.
TPG GP A, LLC
12,328,767 sh · $242.3M
4.02%
Flat
Vanguard Portfolio Management LLC
12,137,727 sh · $238.5M
3.96%
7.2%
Rubric Capital Management LP
10,168,660 sh · $199.8M
3.32%
-7.9%
Vanguard Capital Management LLC
7,710,126 sh · $151.5M
2.52%
1.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.